| Park, Min soo |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
NCT04874129: Phase 1 to Evaluate the Safety and Pharmacokinetic Characteristics of Fixed-dose Combination of YYC506 |
|
|
| Active, not recruiting | 1 | 60 | RoW | YYC506-T and YYC506-A (phase 1), Comparator, YYC506 (phase 1), Test, YYC506-T and YYC506-A (phase 2), YYC506 (phase 2) | Yooyoung Pharmaceutical Co., Ltd. | Dyslipidemias | 05/21 | 07/21 | | |
NCT04840745: The Safety and Pharmacokinetic/Pharmacodynamic Study of CKD-841 in Postmenopausal Female, Phase 1 |
|
|
| Not yet recruiting | 1 | 32 | RoW | CKD-841 A-1 3.75mg, CKD-841, CKD-841 A-1 1.88mg, CKD-841 D 2.92mg, Leuplin Inj. 3.75 mg, Leuplin.Inj | Chong Kun Dang Pharmaceutical, Severance Hospital | Early Puberty | 10/21 | 11/21 | | |
NCT05223101: A Bioequivalence Study Between Telmione 80 mg and Micardis 80 mg in Healthy Adult Volunteers |
|
|
| Recruiting | 1 | 46 | RoW | Telminone 80 mg, Drug: Micardis 80 mg | HK inno.N Corporation | Hypertension | 07/22 | 07/22 | | |
NCT05741437: A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of CKD-378 |
|
|
| Completed | 1 | 24 | RoW | CKD-378, QD, PO Drug: D745, D150, QD, PO, CKD-378 | Chong Kun Dang Pharmaceutical | Type II Diabetes | 08/23 | 09/23 | | |
NCT06395155: A Phase 1 Clinical Trial DHP2306R1 and DHP2306R2 in Healthy Adult Volunteers |
|
|
| Completed | 1 | 54 | RoW | DHP2306R1, DHP2306R2 | Daehwa Pharmaceutical Co., Ltd. | Musculoskeletal Pain | 12/23 | 12/23 | | |
NCT06725992: Study to Evaluate Pharmacokinetic and Pharmacodynamic Drug Interactions and Safety of IY-NS250 and IY-NT-SR |
|
|
| Completed | 1 | 56 | RoW | IY-NS250, IY-NT-SR, Noltec(the brand name) | Il-Yang Pharm. Co., Ltd. | Pharmacokinetics, Pharmacodynamics | 04/24 | 08/24 | | |
NCT06618079: Drug-Drug Interaction Study Between HUC2-565-A and HUC2-565-B |
|
|
| Active, not recruiting | 1 | 46 | RoW | HUC2-565-A, HUC2-565-A and HUC2-565-B, HUC2-565-B, HUC2-565-A and HUC2-565-B | Huons Co., Ltd. | Hypertension | 07/24 | 10/24 | | |
NCT05251506: The Evaluation of Laser Lancing Devices in Adult Type 2 Diabetes Patients |
|
|
| Recruiting | N/A | 80 | RoW | laser lancing device or lancet for blood glucose level measurement | Korea University Guro Hospital, Korea Medical Device Development Fund | Type 2 Diabetes | 03/22 | 12/22 | | |
NCT05515614: Targeted Nutrition for Moderate to Late Preterm Infants |
|
|
| Recruiting | N/A | 200 | US | Targeted Fortification, Enfamil Liquid Human Milk Fortifier, LHMF | Loma Linda University | Premature Birth, Breastmilk Collection, Postnatal Growth Restriction | 12/24 | 12/24 | | |
| Recruiting | N/A | 40000 | Europe, Canada, Japan, US, RoW | Stroke/Thrombectomy/Aneurysm-specific surgical procedures | Medical University of South Carolina | Stroke, Thromboses, Intracranial, Aneurysm, Brain | 01/55 | 01/55 | | |
